data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
KemPharm
(NASDAQ:KMPH)
$4.66
0.14[3.10%]
At close: Jun 29
$4.66
00
After Hours: 4:00PM EDT
Day High/Low4.43 - 4.68
52 Week High/Low4 - 14.01
Open / Close4.55 / 4.66
Float / Outstanding34.2M / 34.4M
Vol / Avg.226.1K / 555K
Mkt Cap160.4M
P/E13.7
50d Avg. Price4.51
Div / Yield-
Payout Ratio-
EPS-0.05
Total Float34.2M

KemPharm (NASDAQ:KMPH), Quotes and News Summary

KemPharm (NASDAQ: KMPH)

Day High/Low4.43 - 4.68
52 Week High/Low4 - 14.01
Open / Close4.55 / 4.66
Float / Outstanding34.2M / 34.4M
Vol / Avg.226.1K / 555K
Mkt Cap160.4M
P/E13.7
50d Avg. Price4.51
Div / Yield-
Payout Ratio-
EPS-0.05
Total Float34.2M
Benzinga - May 16, 2022, 6:12AM
Benzinga - May 12, 2022, 4:39PM
Benzinga - May 5, 2022, 7:34AM
Benzinga - May 3, 2022, 9:03AM
Benzinga - Apr 28, 2022, 1:02PM
Benzinga - Apr 19, 2022, 7:38AM
Benzinga - Mar 30, 2022, 4:14PM
Benzinga - Mar 21, 2022, 10:15AM
Benzinga - Mar 21, 2022, 7:32AM
Benzinga - Mar 16, 2022, 7:34AM
Benzinga - Feb 23, 2022, 7:38AM
Benzinga - Jan 31, 2022, 7:20AM
Benzinga - Jan 20, 2022, 7:00AM
Benzinga - Jan 19, 2022, 4:22PM
Benzinga - Jan 4, 2022, 7:55AM
Benzinga - Dec 20, 2021, 7:31AM
Benzinga - Dec 14, 2021, 7:34AM
Benzinga - Dec 13, 2021, 4:07PM
Benzinga - Nov 10, 2021, 4:44PM
load more
Sector: Health Care.Industry: Pharmaceuticals
KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of treatments for the central nervous system, CNS, and rare disease indications. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, and KP484, which are both based on a prodrug of d-methylphenidate, or d-MPH; KP879, is also based on a prodrug of d-MPH.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-11
REV
Q1 2022Est.ActualSurprise
EPS-0.050-0.050 0.0000
REV3.060M3.965M905.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

KemPharm Questions & Answers

Q
How do I buy KemPharm (KMPH) stock?
A

You can purchase shares of KemPharm (NASDAQ: KMPH) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are KemPharm's (KMPH) competitors?
Q
What is the target price for KemPharm (KMPH) stock?
A

The latest price target for KemPharm (NASDAQ: KMPH) was reported by HC Wainwright & Co. on Monday, January 31, 2022. The analyst firm set a price target for 11.00 expecting KMPH to rise to within 12 months (a possible 136.05% upside). 1 analyst firms have reported ratings in the last year.

Q
Current Stock Price for KemPharm (KMPH)?
A

The stock price for KemPharm (NASDAQ: KMPH) is $4.66 last updated June 29, 2022, 8:00 PM UTC.

Q
Does KemPharm (KMPH) pay a dividend?
A

There are no upcoming dividends for KemPharm.

Q
When is KemPharm (NASDAQ:KMPH) reporting earnings?
A

KemPharm’s Q2 earnings are confirmed for Thursday, August 11, 2022.

Q
Is KemPharm (KMPH) going to split?
A

There is no upcoming split for KemPharm.

Q
What sector and industry does KemPharm (KMPH) operate in?
A

KemPharm is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.